A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or more prior lines of therapy
1. Evaluate the safety and tolerability of TNB-486 when administered as monotherapy;
2. Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for TNB-486 when administered as monotherapy;
3. Evaluate the clinical pharmacology (i.e., pharmacokinetics) of TNB-486 when
administered as monotherapy;
4. Evaluate the clinical activity of TNB-486 when administered as monotherapy.
Biopsy proven B-NHL, including DLBCL, HGBL, transformed indolent NHL including Richter's transformation, mantle cell lymphoma (MCL), FL, or marginal zone lymphoma (MZL).
For Arm B Only: Subject has biopsy proven DLBCL or HGBL
For Arm C only: Subject has biopsy proven FL
Has received at least 2 lines of therapy to which the subject has been either refractory or has subsequently relapsed. In order to be eligible for this study patients must not be candidates for treatment regimens known to provide clinical benefit in B-NHL.
Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
Must have adequate liver, bone marrow and kidney function (eGFR >/= 50 mL/min).
Diagnosed with or treated for another malignancy whose natural history or treatment may interfere with the safety or efficacy assessment of the investigational regimen.
History of central nervous system (CNS) involvement by their B-NHL
History of leukemic presentation of their B-NHL, with the exception of MCL or MZL.
Clinically significant CNS pathology
Received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study drug treatment or has received an SCT and requires ongoing immunosuppressive therapy.
Patients with human immunodeficiency virus (HIV) infection, or patients with chronic or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients with chronic HBV may be enrolled if the HBV viral load is undetectable on suppressive therapy, or if the subject has a documented cure. Subjects with HCV who have a documented cure may be enrolled.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub